Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest baclofen Stories

2014-04-10 12:27:13

Baclofen can be a miracle drug for some people who are addicted to alcohol. NEW YORK, April 10, 2014 /PRNewswire/ -- Baclofen is a medication that can be used for the treatment of addiction to alcohol. It is a medication that has actually been around for a long time. It is a muscle relaxant that is used to treat severe muscle spasticity. Baclofen mainly works at the GABA-B receptor. This causes muscular relaxation. It also causes psychological relaxation, with relief of stress and...

2014-04-02 12:20:48

Commonly used neurological medication proves successful at blocking brain's reward system triggers Relapse is the most painful and expensive feature of drug addiction—even after addicted individuals have been drug-free for months or years, the likelihood of sliding back into the habit remains high. The National Institute on Drug Abuse estimates that 40 to 60 percent of addicted individuals will relapse, and in some studies the rates are as high as 80 percent at six months after...

2013-01-07 08:24:09

CENTENNIAL, Colo., Jan. 7, 2013 /PRNewswire-USNewswire/ -- Julie Hyman, 51, had a stroke at age 37. At the time, she was busy juggling home, family and work, but her lifestyle was stressful in the midst of balancing everything. Like so many people, she ignored the warning signs of her stroke, feeling that she was too young to experience such a devastating event. After her stroke, Julie felt that her life as she knew it was over. She was paralyzed on the left side and only had the use of one...

2012-06-12 10:46:57

Researchers in France and Sweden have discovered how one of the body's own proteins is involved in generating chronic pain in rats. The results, which also suggest therapeutic interventions to alleviate long-lasting pain, are reported in The EMBO Journal. Chronic pain is persistent and often difficult to treat. It is due, at least in part, to changes in molecular signalling events that take place in neurons, alterations that can ultimately disrupt the transmission of nerve signals from the...

2011-07-20 16:52:58

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center. Rush is the only site in Illinois and one of 21 hospitals in the U.S. participating in the trial for Fragile X.  Fragile X syndrome is a neurodevelopmental disorder...

2010-10-18 16:00:33

Baclofen, esomeprazole investigated as treatments The impact of upper GI conditions, like gastroesophageal reflux disease (GERD) and functional dyspepsia, on sleep"”and treatments aimed at providing relief to heartburn/acid reflux patients who suffer from disordered sleep"”were explored in three new studies related to sleep dysfunction presented today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas. Functional dyspepsia is a...

2010-03-23 05:30:00

TOLOCHENAZ, Switzerland, March 23, 2010 /PRNewswire-FirstCall/ -- - Spasticity Affects a Significant Number of Post-Stroke Patients, [1],[2],[3] and Many are not Adequately Treated by Standard Therapy [4] Medtronic, Inc. (NYSE: MDT) today announced the enrollment of the first European patients in the largest randomized controlled trial to date to investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in post-stroke patients affected by spasticity. The announcement...

2008-09-11 12:00:43

US-based biopharmaceutical company XenoPort has announced plans to initiate an exploratory Phase II clinical trial of XP19986 in patients with acute back spasms, which is a debilitating condition affecting approximately two-thirds of patients experiencing lower back pain. XenoPort intends to initiate this two-week, multi-center, double-blind, placebo controlled trial in the fourth quarter of 2008. The primary objective of the study will be to evaluate the safety and tolerability of XP19986...

2008-09-10 09:00:48

XenoPort, Inc. (Nasdaq:XNPT) announced plans to initiate an exploratory Phase 2 clinical trial of XP19986 in patients with acute back spasms, which is a debilitating condition affecting approximately two-thirds of patients experiencing lower back pain. XenoPort intends to initiate this two-week, multi-center, double-blind, placebo controlled trial in the fourth quarter of this year. The primary objective of the study will be to evaluate the safety and tolerability of XP19986 in subjects with...

2008-08-08 12:00:45

Impax Laboratories has announced that IPX056, an investigational extended-release formulation of baclofen, has met its clinical endpoints in a Phase III study of spasticity in multiple sclerosis patients. In a 173-patient, placebo and active comparator-controlled double blind Phase III study with a seven-week open label follow on, IPX056 was shown to be effective versus placebo in reducing spasticity in multiple sclerosis patients. IPX056 is an extended-release formulation of baclofen,...